Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572825 · ClinicalTrials.gov registry record · Phase 1
Assessing the Safety and Tolerability of NMN in DHDDS-CDG
A Phase 1 study, sponsored by Eva Morava-Kozicz.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07572825: Recruiting Phase 1 study, sponsored by Eva Morava-Kozicz.
NCT07572825 is a Phase 1 study that is actively recruiting participants, run by Eva Morava-Kozicz. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07572825, a Phase 1 study, is actively recruiting participants, sponsored by Eva Morava-Kozicz.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.
Primary Outcome
Incidence of AEs will be collected throughout the treatment period and optional long-term safety follow up period.
Interventions
- DRUG Nicotinamide Mononucleotide (NMN) Nucleosidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-05-08 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 1 |
What NCT07572825 shows while recruiting
NCT07572825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Nicotinamide Mononucleotide (NMN) Nucleosidase is the first listed.
NCT07572825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07572825 about?
NCT07572825 is a clinical study titled "Assessing the Safety and Tolerability of NMN in DHDDS-CDG". The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow...
What is the current status of trial NCT07572825?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-05-08. Estimated completion is 2027-08-01.
What interventions are being tested in trial NCT07572825?
The interventions under investigation include: Nicotinamide Mononucleotide (NMN) Nucleosidase (DRUG).
Who is sponsoring clinical trial NCT07572825?
This trial is sponsored by Eva Morava-Kozicz, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07572825's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI